Swiss Lions rankings | 2026 edition
PolyPeptide
PolyPeptide is No. 14 in the Pharma & Biotech ranking, with a score of 18.4 out of 100. It is not among the Swiss Lions 100 for 2026. Headquarters: Baar, canton of Zug.
- Swiss Lions score
- 18.4
- Swiss Lions 100
- Not in the 100 for 2026
- Pharma & Biotech
- 14of 15
About
Baar-based contract development and manufacturing organisation for peptide-based active pharmaceutical ingredients, with six cGMP manufacturing sites in Europe, the United States and India.
PolyPeptide Group is a contract development and manufacturing organisation (CDMO) that produces peptide-based active pharmaceutical ingredients for pharmaceutical and biotechnology companies, from pre-clinical stages to commercial supply. Its roots go back to 1952, and it has been listed on SIX Swiss Exchange since 2021. The group is headquartered in Baar and runs six cGMP-certified manufacturing sites in Strasbourg (France), Braine-l'Alleud (Belgium), Malmö (Sweden), Ambernath (India), and San Diego and Torrance in the United States, including a new large-scale solid-phase peptide synthesis facility in Belgium. It serves around 250 academic, pharmaceutical and biotech customers worldwide. Revenue was EUR 389.3 million in 2025.
- Custom peptide API development and manufacturing
- Commercial-scale peptide API supply
- Large-scale solid-phase peptide synthesis
How the score is made
Global scale
CHF 366m revenue.
Swiss value
Swiss headquarters, design and R&D; made abroad.
Global visibility
Online attention across languages, and worldwide search interest.
Impact
Near-term target validated. Not a certified B Corp.
Philanthropy
No charitable foundation found.
Impact and philanthropy together make up the impact measure. How the ranking works.
Key figures
- Revenue used in the ranking
- CHF 366m2025, company
Shares and listing
- Stock exchange
- SIX Swiss ExchangeTicker PPGN
- ISIN
- CH1593449767
- Market value
- CHF 1.5 billionAt the close on 23 October 2026. Source: stockanalysis.com.
- Free float
- 40.6%Shares not held by large long-term shareholders. Source: in.marketscreener.com.
Profit, dividends and employee numbers are published in the company's annual report.
We have not found a published figure for employees in Switzerland for 2025 or 2026, and dividends paid to Swiss shareholders are not published, so neither is shown.
Profile
- Headquarters
- BaarCanton of Zug
- Language region
- German-speaking
- Category
- Pharma & Biotech
- Ownership
- Listed, controlled by Frederik Paulsen
- Chief executive
- Juan-José GonzalezSince 2023. Source
- Chair
- Peter WildenSource
- Founded
- 1996
In Switzerland
- Baar ZGHeadquarters
Over time
| Year | Revenue | Employees worldwide |
|---|---|---|
| 2025 | EUR 389m | 1,395 FTE |
| 2024 | EUR 337m | 1,291 FTE |
| 2023 | EUR 320m | 1,202 FTE |
As reported by the company, in its reporting currency. Group figures where the brand is part of a group only if stated.
Milestones
- 1952Origins of the PolyPeptide business.
- 2021Initial public offering on SIX Swiss Exchange (ticker PPGN).
- 2023Juan-José Gonzalez becomes chief executive on 12 April.
- 2025Revenue grows 15.6% to EUR 389.3 million.
Also in Pharma & Biotech
1RocheScore 77.2
2NovartisScore 75.5
3LonzaScore 56.3
4SandozScore 52.1
5FerringScore 49.8
6SiegfriedScore 44.1
See all 15 brands in Pharma & Biotech.
Sources
- Revenue used in the ranking: report.polypeptide.com (2025).
- Company profile, sites, history and milestones: report.polypeptide.com, polypeptide.com.
- Climate target: Science Based Targets initiative dashboard, October 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or PolyPeptide can publish figures for the next edition, tell us. Corrections are recorded with their source.